Table 3. The impact of formerly described parameters linked to outcome in our series.
| Parameter (number of patients) | Median PFS (months) | P | Median OS (months) | P |
|---|---|---|---|---|
| Neutrophils >4500 mm−3 (47) | 4 | 0.018 | 9 | 0.05 |
| Neutrophils ⩽4500 mm−3 (29) | 9 | 14 | ||
| Platelets >400 000 mm−3 (13) | 2 | 0.0001 | 5 | 0.0003 |
| Platelets ⩽400 000 mm−3 (63) | 7 | 14 | ||
| ECOG PS>0 (48) | 3 | 0.27 | 8 | 0.16 |
| ECOG PS 0 (28) | 11 | 17 | ||
| LDH >1.5ULN (4) | 1.5 | <0.0001 | 2 | 0.0003 |
| LDH ⩽1.5ULN (72) | 6 | 14 | ||
| Hb low (<11.5 g dl−1 (women) or <13 g dl−1 (men)) (51) | 6 | 0.64 | 11 | 0.62 |
| Hb normal (25) | 7 | 13 | ||
| Corrected Calcium >10 mg dl−1 (10) | 5 | 0.60 | 13.5 | 0.57 |
| Corrected Calcium ⩽10 mg dl−1 (66) | 6 | 11 | ||
| Time from nephrectomy to systemic treatment <12 months (41) | 4 | 0.92 | 11 | 0.92 |
| Time from nephrectomy to systemic treatment >12 months (35) | 6 | 11 | ||
| Time from diagnosis metastases to start TKIs ⩽6 months (35) | 3 | 0.20 | 8 | 0.46 |
| Time from diagnosis metastases to start TKIs >6 months (41) | 8 | 17 | ||
| Liver metastases (16) | 3 | 0.074 | 7 | 0.019 |
| No liver metastases (60) | 6 | 13 | ||
| No nephrectomy (8) | 1.5 | 0.019 | 11 | 0.15 |
| Nephrectomy (68) | 6 | 11 | ||
| Sorafenib (19) | 6 | 0.70 | 10 | 0.46 |
| Sunitinib (57) | 6 | 11 | ||
| Non-clear cell (9) | 3 | 0.28 | 7 | 0.13 |
| Clear cell (67) | 6 | 12 | ||
| Sarcomatoid features (15) | 3 | 0.21 | 7 | 0.29 |
| No sarcomatoid features (61) | 6 | 12 |
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; LDH=lactate dehydrogenase; OS=overall survival; PFS=progression-free survival; TKI=tyrosine kinase inhibitor.